admin

Chinese AI stocks surge after Beijing unveils measures to boost AI adoption and ease listings; Zhipu and MiniMax jump over 23%, while Alibaba and Tencent extend declines

A total of nine analysts have coverage on the Tata Communications stock and of them six have a “hold” rating, two have a “buy” rating and one has a “sell” rating.

George Thomas, Fund Manager-Equity at Quantum AMC, which managed assets worth over ₹3,948.11 crore as of March 2026, believes lower crude prices could benefit oil marketing companies, gas utilities and businesses dependent on crude derivatives. However, he cautioned investors against…

Blue Cloud Softech Solutions said the discussions are currently at a preliminary stage and are non-binding in nature. Both parties have established a framework for sharing information and assessing potential areas of collaboration in AI and digital technology.

Street sentiment on the CONCOR stock remains mixed, with 13 of the 20 analysts covering CONCOR giving it a ‘buy’ rating, while two suggest ‘hold’ and five have a ‘sell’ recommendation.

Goldman Sachs upgrades Allegiant Travel to buy after closing its $1.5 billion Sun Country deal, sees 30% upside, citing growth, pricing power, and fuel hedge benefits.

Brokerage firm Motilal Oswal said Delhivery’s express segment recorded 73% volume growth during the fourth quarter of FY26, including the impact of the Ecom Express acquisition, despite a challenging operating environment marked by the West Asia crisis and the seasonal…

According to the VAHAN registration data till June 21, total vehicle registrations have reached 17 lakh units, up almost 20% from 14.2 lakh units recorded in the corresponding period last year.

Srikanth Velamakanni, Co-Founder and Group Chief Executive of Fractal said technology spending is growing at 13% annually, far outpacing global economic growth of 2-2.5%, creating a significant opportunity for the industry.

Citi believes a series of near-term triggers in the US market could support further upside for the stock. These include the potential approval of generic Flovent (gFlovent), the launch of generic Ventolin (gVentolin), and Cipla’s growing presence in the Nintedanib…